"The Obesity Drug" is about to be released in Korea...Ministry of Food and Drug Safety "requires careful administration"

The Ministry of Food and Drug Safety emphasized the need for careful administration as various side effects can occur in relation to obesity treatment injections, which have gained attention due to the use of global celebrities.

The Ministry of Food and Drug Safety said Novo Nordisk's obesity injection "Wigobi," which will be released in Korea this month, should be carefully used according to medical professionals' prescriptions and approved usage only for highly obese patients.

The injection is a specialized drug for adult obese patients and is known to have side effects such as headache, diarrhea, constipation, cholelithiasis, hair loss, and acute pancreatitis.

In addition, patients with diabetes or hypoglycemia may occur due to deterioration of kidney function due to dehydration, so patients with the disease should be carefully administered.

The Ministry of Food and Drug Safety urged people not to buy the obesity treatment online without being prescribed, and emphasized that it plans to check over-advertising behavior in medical institutions.